drugset
drugset / Trial / NCT05105672

A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer

NCT05105672 ↗

Phase 2 Unknown 20 enrolled The Affiliated Hospital of Xuzhou Medical University
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, single-center phase II clinical study to explore the efficacy and safety of sintilimab combined with concurrent chemoradiation therapy as treatment in women with locally advanced cervical cancer.

Timeline

Start
2021-03-08
Primary completion
2023-03-01
Completion
2024-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous

Indications

cervical cancer